|
|
|
04 December 2025
Phil Kerpen, President and Founder of American Commitment, discusses the recent drug-pricing deal negotiated by the Trump administration with the United Kingdom, the multiple benefits the agreement will have for Americans and drug innovation, why taxpayer subsidies to health insurers will not lower healthcare costs, and why price controls for credit card transactions are a bad idea.
0:00
0:00
Related Podcasts
04 April 2024
Doug Kelly, CEO of American Edge Project ("AEP"), discusses AEP's recently released study, "American Innovation Under Siege: Venture Capital Data Reveals Risks from Rising Global Regulatory Overreach," how heavy-handed regulations negatively impact innovation, jobs and U.S. military readiness, and what recommendations the study offers on how the U.S. can win the innovation race against China.
17 September 2020
Sally Pipes, President, CEO and Thomas W. Smith Fellow in Health Care Policy at the Pacific Research Institute, discusses President Trump’s recent executive order regarding drug pricing, how importing foreign drug price controls could curtail innovation and limit access to the newest drugs, and why the timing of such a policy is wrong amid the ongoing COVID-19 pandemic.
14 August 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at the Center for Individual Freedom, discusses President Trump's executive orders on drug pricing and the negative consequences of government price controls on innovation and to consumers.
03 May 2019
Phil Kerpen, President of American Commitment, discusses prescription drug prices, the fundamental problems with importing foreign price controls, and the steps Congress can take to improve the system.
20 January 2017
Clark Neily, Senior Attorney at the Institute for Justice, discusses the sharing economy, services such as Uber, Lyft, and Airbnb, and regulatory barriers to innovation.
09 January 2015
Leighton Steward, Chairman of Plants Need CO2, discusses a report from a team of former NASA scientists that concludes there is no convincing physical evidence of catastrophic human-caused global warming and the American people's rejection of President Obama's Global Climate Deal.
